Biosimilars Market Segmentation:
Product Type Segment Analysis
The recombinant non-glycosylated proteins segment is poised to garner highest biosimilars market share by 2034, backed by growing concern of rising incidences of diabetes along with surge in the spread of diabetes worldwide. Furthermore, recombinant non-glycosylated proteins are used for the treatment of the diabetes. For instance, it was estimated that 1.5 million deaths were directly caused by diabetes worldwide, it was the 9th leading cause of death in 2019.
Application Segment Analysis
The oncology segment will account for largest biosimilars market share by 2034, owing to rising number of cancer cases across the globe. Moreover, biosimilars have been created and approved to deliver efficient results in breast cancer treatment, colorectal cancer treatment, and other solid tumor treatments. Chemotherapy and other cancer therapies are combined with biosimilars to increase cancer patient chances of survival and quality of life.
Our in-depth analysis of the global biosimilars market includes the following segments:
|
By Product Type |
|
|
By Technology |
|
|
By Application |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of biosimilars is evaluated at USD 32.55 billion.
Biosimilars Market size was over USD 28.61 billion in 2024 and is poised to exceed USD 128.4 billion by 2034, growing at over 16.2% CAGR during the forecast period i.e., between 2025-2034.
Europe is expected to dominate largest industry share by 2034.
The key market players include Biocon Limited, Amgen Inc., Novartis AG, Intas Pharmaceuticals Ltd., BioXpress Therapeutics SA, Genor Biopharma Co. Ltd, Allergan plc (AbbVie Inc.), Coherus BioSciences, Inc., Pfizer Inc., Reliance Life Sciences Private Limited.
